DK1969127T4 - Fremgangsmåde til fremstilling af biologisk aktivt vitamin K-afhængige proteiner med rekombinante fremgangsmåder - Google Patents
Fremgangsmåde til fremstilling af biologisk aktivt vitamin K-afhængige proteiner med rekombinante fremgangsmåder Download PDFInfo
- Publication number
- DK1969127T4 DK1969127T4 DK06848864.2T DK06848864T DK1969127T4 DK 1969127 T4 DK1969127 T4 DK 1969127T4 DK 06848864 T DK06848864 T DK 06848864T DK 1969127 T4 DK1969127 T4 DK 1969127T4
- Authority
- DK
- Denmark
- Prior art keywords
- factor
- protein
- vitamin
- dependent
- cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6429—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6437—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21005—Thrombin (3.4.21.5)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
- C12Y101/04—Oxidoreductases acting on the CH-OH group of donors (1.1) with a disulfide as acceptor (1.1.4)
- C12Y101/04001—Vitamin-K-epoxide reductase (warfarin-sensitive) (1.1.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y401/00—Carbon-carbon lyases (4.1)
- C12Y401/01—Carboxy-lyases (4.1.1)
- C12Y401/0109—Peptidyl-glutamate 4-carboxylase (4.1.1.90)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Claims (14)
1. Fremgangsmåde til fremstilling af et rekombinant biologisk aktivt Faktor IX-proteinprodukt, hvilken fremgangsmåde omfatter trinnene med: transfektering af en CHO-celle med et gen, der koder for Faktor IX-proteinproduktet, der operativt er forbundet med en kinesisk hamster-elongeringsfaktor 1-a- (CHEF-1) promoter, og mindst to gener enten samtidigt eller sekventielt; og høstning af Faktor IX-proteinproduktet, hvorved cellen fremstiller biologisk aktivt Faktor IX-proteinprodukt, som målt med reference til Faktor IX-standard Mononine i en mængde på mindst 15 mg/L; og hvor de mindst to gener omfatter en genkodende vitamin K-afhængig epoxidreduktase (VKOR) og en genkodende vitamin K-afhængig γ-glutamylcarboxylase (VKGC).
2. Fremgangsmåde ifølge krav 1, hvor mindst ét af generne er overudtrykt.
3. Fremgangsmåde ifølge krav 2, hvor det overudtrykte gen er operativt forbundet med en kinesisk hamster-elongeringsfaktor 1-a- (CHEF1) promoter.
4. Fremgangsmåde ifølge krav 1, hvor mindst omkring 75 % af glutaminsyreresteme i gla-domænet af det biologisk aktive Faktor IX proteinprodukt er gamma-carboxyleret.
5. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor mindst 50 %, mindst 70 % eller mindst 80 % af Faktor IX-proteinet er biologisk aktivt.
6. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor det biologisk aktive Faktor IX-protein fremstilles i en mængde på mindst 20 mg/F.
7. Fremgangsmåde ifølge et hvilket som helst af de foregående krav, hvor transfekteringen er sekventiel, og hvor transfekteringen af pattedyrscellen endvidere omfatter: udvælgelse af celler, der udtrykker høje niveauer af Faktor IX-proteinproduktet, VKOR eller VKGC; kloning af de udvalgte celler og amplifiering af de klonede celler.
8. Fremgangsmåde ifølge krav 7, hvor trinnet med transfektering med mindst to gener udføres før trinnet med transfektering med genet, der koder for Faktor IX-proteinet.
9. Fremgangsmåde ifølge krav 7, hvor trinnet med transfektering med genet, der koder for Faktor IX-proteinet, udføres før trinnet med transfektering med de mindst to gener.
10. Fremgangsmåde ifølge et hvilket som helst af kravene 7 til 9, hvor CHO-cellen er udvalgt til ekspression af endogene niveauer af én eller flere behandlingsfaktorer før transfektering.
11. Rekombinant CHO-celle omfattende et gen, der koder for et Faktor IX-protein, der er operativt forbundet med en kinesisk hamster-elongeringsfaktor I-a- (CHEF-1) promoter og mindst to gener, der er operativt forbundet med mindst én promoter, hvor cellen fremstiller biologisk aktivt FIX-protein i en mængde på mindst 15 mg/L, som målt med reference til Faktor IX-standard Mononine, hvor de mindst to gener omfatter en genkodende vitamin K-afhængig epoxidreduktase (VKOR) og en genkodende vitamin K-afhængig γ-glutamyl carboxylase (VKGC).
12. Rekombinant celle ifølge krav 11, hvor mindst ét gen er overudtrykt.
13. Rekombinant celle ifølge krav 12, hvor det overudtrykte genprodukt er operativt forbundet med en kinesisk hamster-elongeringsfaktor 1-a- (CHEFI) promoter.
14. Fremgangsmåde til fremstilling af et rekombinant biologisk aktivt Faktor IX-proteinprodukt, der omfatter trinnene med: (a) transfektering af en CHO-celle med en gen, der koder for Faktor IX-protein, der er operativt forbundet med en kinesisk hamster-elongeringsfaktor 1-a- (CHEF 1) promoter; (b) udvælgelse af celler, der udtrykker høje niveauer af Faktor IX-proteinproduktet; (c) transfektering af de udvalgte celler med mindst to gener, hvor de mindst to gener omfatter en genkodende vitamin K-afhængig epoxidreduktase (VKOR) og en genkodende vitamin K-afhængig γ-glutamylcarboxylase (VKGC); (d) gentagelse af trin (b); (e) eventuelt gentagelse af trinnene (a) og/eller (c) efterfulgt af (b); (f) kloning af de udvalgte celler; (g) dyrkning af de klonede celler og (h) høstning af Faktor IX-proteinproduktet fra de klonede celler i en mængde på mindst 15 mg/L.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US75264205P | 2005-12-21 | 2005-12-21 | |
PCT/US2006/048954 WO2007075976A2 (en) | 2005-12-21 | 2006-12-21 | Method of producing biologically active vitamin k dependent proteins by recombinant methods |
Publications (2)
Publication Number | Publication Date |
---|---|
DK1969127T3 DK1969127T3 (da) | 2014-09-22 |
DK1969127T4 true DK1969127T4 (da) | 2017-10-16 |
Family
ID=38051872
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK06848864.2T DK1969127T4 (da) | 2005-12-21 | 2006-12-21 | Fremgangsmåde til fremstilling af biologisk aktivt vitamin K-afhængige proteiner med rekombinante fremgangsmåder |
Country Status (11)
Country | Link |
---|---|
US (6) | US20080045453A1 (da) |
EP (2) | EP2385125A3 (da) |
JP (3) | JP5526332B2 (da) |
AU (1) | AU2006331501B2 (da) |
CA (1) | CA2633661C (da) |
DK (1) | DK1969127T4 (da) |
ES (1) | ES2503365T5 (da) |
PL (1) | PL1969127T5 (da) |
PT (1) | PT1969127E (da) |
SI (1) | SI1969127T2 (da) |
WO (1) | WO2007075976A2 (da) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2004275828B2 (en) | 2003-09-23 | 2010-04-29 | University Of North Carolina At Chapel Hill | Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage |
GB0324044D0 (en) * | 2003-10-14 | 2003-11-19 | Astrazeneca Ab | Protein |
CA2542017A1 (en) | 2003-10-14 | 2005-05-06 | Baxter International, Inc. | Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives |
JP2008532544A (ja) | 2005-03-15 | 2008-08-21 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 活性ビタミンk依存性タンパク質を生産するための方法及び組成物 |
CN101198696B (zh) * | 2005-04-13 | 2014-02-26 | 阿斯利康(瑞典)有限公司 | 包含产生需要γ-羧化的蛋白质用的载体的宿主细胞 |
PL1969127T5 (pl) † | 2005-12-21 | 2018-02-28 | Cnj Holdings, Inc | Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji |
EP2517714A1 (en) * | 2007-04-26 | 2012-10-31 | Inspiration Biopharmaceuticals, Inc. | Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same |
US8206967B2 (en) * | 2007-07-06 | 2012-06-26 | Medimmune Limited | Method for production of recombinant human thrombin |
DK2337849T3 (da) | 2008-09-15 | 2018-10-01 | Uniqure Biopharma B V | Faktor ix-polypeptidmutant, anvendelser deraf og fremgangsmåde til fremstiling deraf |
EP2451963B1 (en) * | 2009-07-10 | 2014-04-30 | CSL Limited | Method of increasing the expression yield of vitamin k-dependent proteins |
EP2484761A4 (en) * | 2009-10-01 | 2013-11-27 | Toto Ltd | DNA CONSTRUCT AND METHOD FOR PRODUCING RECOMBINANT CHO CELLS THEREWITH |
JP5851410B2 (ja) * | 2009-10-30 | 2016-02-03 | シーエヌジェイ ホールディングス、インク. | 組換えビタミンk依存性タンパク質の生成法 |
EP2655607A4 (en) | 2010-12-21 | 2014-05-14 | Univ North Carolina | METHOD AND COMPOSITIONS FOR PRODUCING ACTIVE VITAMIN K-DEPENDENT PROTEINS |
US20130230901A1 (en) * | 2012-02-14 | 2013-09-05 | Portola Pharmaceuticals, Inc. | Process for making recombinant antidote to factor xa inhibitor |
CA2904125C (en) * | 2013-03-12 | 2022-06-07 | Cmc Icos Biologics, Inc. | Improved recombinant protein expression using a hybrid chef1 promoter |
JP5830486B2 (ja) * | 2013-03-29 | 2015-12-09 | シスメックス株式会社 | 組換えバキュロウイルスおよびその利用 |
RU2585532C2 (ru) * | 2014-01-31 | 2016-05-27 | Федеральное государственное учреждение "Федеральный исследовательский центр "Фундаментальные основы биотехнологии" Российской академии наук"(ФИЦ Биотехнологии РАН) | Плазмида для экспрессии рекомбинантного фактора свёртываемости крови ix человека, клетка сно - продуцент рекомбинантного фактора свёртываемости крови ix человека и способ получения указанного фактора |
ES2803773T3 (es) | 2015-12-02 | 2021-01-29 | CSL Behring Lengnau AG | Medios mejorados para la expresión de proteínas recombinantes dependientes de vitamina k |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
US4599308A (en) | 1981-10-06 | 1986-07-08 | Hamer Dean H | Protein from SV40 recombinants |
DE3380848D1 (en) | 1982-08-04 | 1989-12-21 | Nat Res Dev | Molecular cloning of the gene for human anti-haemophilic factor ix |
AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
FR2564106B1 (fr) | 1984-05-09 | 1988-04-22 | Transgene Sa | Vecteurs d'expression du facteur ix, cellules transformees par ces vecteurs et procede de preparation du facteur ix. |
US4879236A (en) | 1984-05-16 | 1989-11-07 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
US4745057A (en) | 1984-05-18 | 1988-05-17 | Eli Lilly And Company | Method, vectors and transformants for high expression of heterologous polypeptides in yeast |
JPH082307B2 (ja) | 1984-05-22 | 1996-01-17 | トランスジ−ン ソシエテ アノニム | 第▲ix▼因子の製造方法 |
US4912038A (en) | 1984-12-11 | 1990-03-27 | California Biotechnology Inc. | Recombinant DNA sequence encoding alveolar surfactant protein |
US4879224A (en) | 1985-01-10 | 1989-11-07 | Biogen, Inc. | DNA sequences, recombinant DNA molecules and processes for producing human phospholipase inhibitor polypeptides |
US4761371A (en) | 1985-02-12 | 1988-08-02 | Genentech, Inc. | Insulin receptor |
JP2584443B2 (ja) * | 1985-04-22 | 1997-02-26 | ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド | 活性化▲i▼▲x▼因子の高収率産生 |
FR2600334B1 (fr) | 1986-06-23 | 1989-05-12 | Transgene Sa | Vecteurs d'integration dans les cellules eucaryotes assurant l'expression du facteur ix, lignees celullaires obtenues et procede pour leur preparation |
US4877729A (en) | 1986-07-14 | 1989-10-31 | Genetics Institute, Inc. | Recombinant DNA encoding novel family of primate hematopoietic growth factors |
FR2638643B1 (fr) | 1988-11-09 | 1991-04-12 | Transgene Sa | Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants |
WO1992001795A1 (en) * | 1990-07-23 | 1992-02-06 | Zymogenetics, Inc. | Gamma-carboxylase and methods of use |
EP0785273A1 (en) | 1990-11-26 | 1997-07-23 | Genetics Institute, Inc. | Paired basic amino acid converting enzyme and DNA sequence encoding it |
US5965789A (en) * | 1991-01-11 | 1999-10-12 | American Red Cross | Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals |
US5268275A (en) * | 1991-05-08 | 1993-12-07 | The University Of North Carolina At Chapel Hill | Vitamin K-dependent carboxylase |
US5714583A (en) | 1995-06-07 | 1998-02-03 | Genetics Institute, Inc. | Factor IX purification methods |
US5888809A (en) * | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
WO2000054787A1 (en) * | 1999-03-16 | 2000-09-21 | The Children's Hospital Of Philadelphia | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
WO2002029045A2 (en) * | 2000-10-02 | 2002-04-11 | Novo Nordisk A/S | Method for the production of vitamin k-dependent proteins |
AU2004275828B2 (en) * | 2003-09-23 | 2010-04-29 | University Of North Carolina At Chapel Hill | Methods and compositions for the correlation of single nucleotide polymorphisms in the vitamin K epoxide reductase gene and warfarin dosage |
GB0324044D0 (en) * | 2003-10-14 | 2003-11-19 | Astrazeneca Ab | Protein |
CA2590284A1 (en) † | 2004-12-08 | 2006-06-15 | Icos Corporation | Recombinant method for making multimeric proteins |
WO2006067116A1 (en) * | 2004-12-21 | 2006-06-29 | Novo Nordisk Health Care Ag | Expression of gamma-carboxylated polypeptides in gamma-carboxylation deficient host systems |
WO2006089613A1 (en) * | 2005-02-28 | 2006-08-31 | Baxter International Inc. | Recombinant co-expression of vitamin k epoxide reductase subunit 1 to improve vitamin k dependent protein expression |
JP2008532544A (ja) * | 2005-03-15 | 2008-08-21 | ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル | 活性ビタミンk依存性タンパク質を生産するための方法及び組成物 |
CN101198696B (zh) * | 2005-04-13 | 2014-02-26 | 阿斯利康(瑞典)有限公司 | 包含产生需要γ-羧化的蛋白质用的载体的宿主细胞 |
PL1969127T5 (pl) † | 2005-12-21 | 2018-02-28 | Cnj Holdings, Inc | Metoda wytwarzania biologicznie czynnych białek zależnych od witaminy K metodami rekombinacji |
-
2006
- 2006-12-21 PL PL06848864T patent/PL1969127T5/pl unknown
- 2006-12-21 EP EP11157194A patent/EP2385125A3/en not_active Withdrawn
- 2006-12-21 SI SI200631827T patent/SI1969127T2/sl unknown
- 2006-12-21 US US11/643,563 patent/US20080045453A1/en not_active Abandoned
- 2006-12-21 DK DK06848864.2T patent/DK1969127T4/da active
- 2006-12-21 PT PT68488642T patent/PT1969127E/pt unknown
- 2006-12-21 AU AU2006331501A patent/AU2006331501B2/en not_active Ceased
- 2006-12-21 EP EP06848864.2A patent/EP1969127B8/en active Active
- 2006-12-21 JP JP2008547588A patent/JP5526332B2/ja active Active
- 2006-12-21 WO PCT/US2006/048954 patent/WO2007075976A2/en active Application Filing
- 2006-12-21 CA CA2633661A patent/CA2633661C/en active Active
- 2006-12-21 ES ES06848864.2T patent/ES2503365T5/es active Active
-
2012
- 2012-11-19 US US13/681,021 patent/US20130266982A1/en not_active Abandoned
-
2013
- 2013-07-26 JP JP2013155589A patent/JP2013223514A/ja not_active Revoked
-
2015
- 2015-04-13 US US14/685,262 patent/US20160108449A1/en not_active Abandoned
-
2016
- 2016-11-21 JP JP2016225684A patent/JP2017046717A/ja active Pending
-
2018
- 2018-01-19 US US15/875,373 patent/US20190032101A1/en not_active Abandoned
-
2020
- 2020-06-02 US US16/889,986 patent/US20210095323A1/en not_active Abandoned
-
2022
- 2022-10-20 US US17/970,051 patent/US20230287471A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2633661C (en) | 2019-06-04 |
US20210095323A1 (en) | 2021-04-01 |
EP1969127B2 (en) | 2017-07-12 |
EP1969127B8 (en) | 2017-12-13 |
US20230287471A1 (en) | 2023-09-14 |
JP2017046717A (ja) | 2017-03-09 |
EP2385125A2 (en) | 2011-11-09 |
ES2503365T3 (es) | 2014-10-06 |
PL1969127T5 (pl) | 2018-02-28 |
WO2007075976A3 (en) | 2007-10-04 |
DK1969127T3 (da) | 2014-09-22 |
WO2007075976A2 (en) | 2007-07-05 |
US20130266982A1 (en) | 2013-10-10 |
AU2006331501A1 (en) | 2007-07-05 |
US20160108449A1 (en) | 2016-04-21 |
CA2633661A1 (en) | 2007-07-05 |
ES2503365T5 (es) | 2017-10-31 |
AU2006331501B2 (en) | 2013-09-05 |
JP2009521224A (ja) | 2009-06-04 |
EP2385125A3 (en) | 2012-04-11 |
EP1969127A2 (en) | 2008-09-17 |
EP1969127B1 (en) | 2014-06-18 |
JP2013223514A (ja) | 2013-10-31 |
SI1969127T1 (sl) | 2014-12-31 |
PT1969127E (pt) | 2014-09-23 |
US20190032101A1 (en) | 2019-01-31 |
PL1969127T3 (pl) | 2014-11-28 |
SI1969127T2 (sl) | 2017-10-30 |
US20080045453A1 (en) | 2008-02-21 |
JP5526332B2 (ja) | 2014-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230287471A1 (en) | Method of producing biologically active vitamin k dependent proteins by recombinant methods | |
US20230272360A1 (en) | Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same | |
JP2016154537A (ja) | ヒト細胞系における組換えヒトタンパク質の無血清安定トランスフェクションおよび製造 | |
AU2010269072B9 (en) | Method of increasing the expression yield of vitamin K-dependent proteins | |
AU2013211534B2 (en) | Method of producing biologically active vitamin K dependent proteins by recombinant methods | |
AU2016200807A1 (en) | Method of producing biologically active vitamin K dependent proteins by recombinant methods | |
AU2016238889B2 (en) | Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same | |
EP2494040B1 (en) | Method of producing recombinant vitamin k dependent proteins | |
AU2014202989B2 (en) | Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same |